The NTera-2 clone 13 cell line (Thompson et al, 1984) was cloned from the original Tera-2 cell line initially derived from the pulmonary metastasis of a 22-year-old male Caucasian patient (Fogh et al, 1977) . The GCT 27 C-4 embryonal carcinoma cell line was isolated from a malignant primary testicular teratoma (Pera et al, 1987) . Both cell lines were maintained in a mixture of MEMalpha medium and HAMS F12 1:1 supplemented with 10% fetal bovine serum, 50 µg mL -1 penicillin, 100 µg mL -1 streptomycin, 2.5% HEPES with 15 mL L -1 0.833% sodium hydroxide.
Experimental animals
Male SCID mice were purchased at 6-7 weeks of age from the Walter and Eliza Hall Institute Breeding Facility, Melbourne, Australia and housed in a temperature-controlled, specific pathogen-free room (23°C, 12h light-dark regime) with free access to water and a standard diet (Norco, Lismore, NSW, Australia). Tumour cells were implanted when the mice were 8 weeks of age. The study was approved by the Group 5 Animal Experimental Ethics Committee of the University of Queensland and performed according to NHMRC Guidelines (AEEC Approval Number SURG/394/98, SURG/569/99).
Xenograft model
NSGCT tumour cells were implanted by injection in the exteriorized left testis of anaesthetized mice (1 × 10 6 viable cells in 0.25 mL PBS). Mice were culled when the apparent size of the tumour approached 1 cm 3 . The testes, viscera, retroperitoneal lymph nodes, heart, lungs and brain were harvested, weighed and preserved for histological analysis. Tumour burden was defined as the weight of the tumour-affected testis expressed as a percentage of the animal's total body weight.
Histology
Tissues taken for histological study were fixed in 10% buffered formalin for a minimum of 24 hours. The organs were then embedded in paraffin and sectioned. Sections were routinely processed and stained with haematoxylin and eosin. 4 µm thick sections were immunostained with antibodies against CD30 (DAKO, 1/30 dilution), S100 (DAKO, 1/4000 dilution), GFAP (DAKO, 1/7 dilution), AE1/AE3 (Roche, 1/600 dilution), CAM 5.2 (Becton Dickinson, 1/20 dilution) and PLAP (DAKO, 1/100 dilution). The peroxidase-antiperoxidase method was used to detect specific antibody binding. 
RESULTS

Xenograft model of human NSGCT
The requirements for a successful model were met by implanting 1 × 10 6 viable NTera-2 C-13 cells in the left testis of male SCID mice. Tumours developed in all mice and approached the 1 cm 3 size end point (less than 5% of host animal's normal total body weight) within 4 weeks. Post-mortem examination of these mice revealed the presence of metastases in sites consistent with NSGCT progression in human patients (see below and Discussion). Repeated use of this model has demonstrated the reproducibility of this technique (100% occurrence of primary tumours, mean tumour burden at 4 weeks: 3.68 ± 0.23%, n = 20).
The GCT 27 C-4 cell line did not prove to be as suitable for establishment of an animal model of human NSGCT. Primary tumours developed over a longer time period (6-7 weeks) and were less consistent in size and appearance, although the pattern of metastasis was identical to that observed with the NTera-2 C-13 cell line.
Physical features of the NTera-2 C-13 model of NSGCT
During the 4-week period of tumour development, the mice exhibited no symptoms or signs of clinical illness apart from a visible or palpable lump in the lower abdomen or scrotum. The rapid growth of the tumours was externally visible, with lumps apparent in the scrotum and lower perineum. As these tumours increased in size, they generally moved higher into the abdomen and post mortem, were located in the groin adjacent to the bladder.
Macroscopically, the primary tumours were large, ovoid and mobile in the lower abdomen, involving the entire testis (Figure 1 ). The tumours remained discrete without any evidence of malignant adhesion to adjacent structures. There was no visible evidence of ascites or seeding of tumour cells in the abdomen and no obvious nodules in the viscera or lungs. Musculoskeletal structures appeared macroscopically normal. Visible secondary tumours were evident in the retroperitoneal lymph nodes in the left renal hilar lymph region.
Histology of the NTera-2 C-13 model of NSGCT
Histological examination of the testicular tumours showed a poorly differentiated malignancy composed of sheets of tumour cells surrounding intact seminiferous tubules (Figure 2A ). The cells had large vesicular nuclei with clumped chromatin, one or more large nucleoli, and indistinct cytoplasm. There was marked overlapping of nuclei and cell crowding. A high mitotic and apoptotic rate was identified. In other areas there was evidence of neuroepithelial differentiation with obvious rosette formation. Focally the tumour cells were arranged in an eosinophilic fibrillary background resembling glial differentiation. Immunoperoxidase stains revealed focal positive staining for CD30 in the large cell areas with patchy weak staining for CAM 5.2 (data not shown). The background glial areas were positive for S100 and GFAP and there was no positive staining for PLAP (data not shown).
These features are consistent with human NSGCT, with diagnostic characteristics of both embryonal carcinoma and immature teratoma (teratocarcinoma). Histological examination of other organs revealed deposits of histologically identical tumour in numerous sites in all animals. Tumour was identified in liver ( Figure 2B ) and lung ( Figure 2C ). Retroperitoneal soft tissue deposits were evident and focally these abutted the capsule of the kidney. Tumour was seen clearly within an endothelial lined lymphovascular space within the retroperitoneal tissues ( Figure  2D ). Metastatic deposits were also identified within the adrenal cortex and pancreas (data not shown). No metastases were identified within the kidney itself or within heart, brain or spleen.
DISCUSSION
In the past, tumour models were based on tumours that developed spontaneously in certain species, or as a result of specific genetic abnormalities that arose either from breeding programmes or the deliberate alteration of certain genes (transgenic or 'knock-out' lines). Although valuable in studies of developmental processes, these models have not proved as useful for cancer research. Testicular germ cell tumours are particularly difficult to study using these approaches as human tumours differ markedly from spontaneous testicular tumours observed in mice (Walt et al, 1993) .
Xenograft models using single-cell suspensions of tumour cells provide a distinct advantage in that cells may be studied and manipulated in vitro, complementing research performed in vivo. A number of studies have used heterotopic xenografts (most often generated by implanting tumour tissue or cells subcutaneously) to study the growth rates of tumours, the efficacy of therapeutic compounds and/or the biological properties of the tumour in vivo. Whilst these tumours are seen to grow readily and are easily monitored, these models rarely exhibit clinically important features such as metastasis. Xenograft tumours are more likely to develop in a clinically relevant way and metastasize when orthotopically implanted, where environmental conditions more accurately reflect many of the tumour-host cell interactions that take place during naturally occurring tumour development and progression (Fidler, 1990) . Thus, the use of orthotopic xenografts is critical in generating clinically representative models of human disease.
Recently, Konaka et al (1999) described the first orthotopic xenograft model of human testicular germ cell tumour, where wedges of heterotopically xenografted human seminoma were implanted orthotopically in the testes of SCID mice. This model produced clinically relevant metastases and therefore represents a significant advance in the study of seminomatous tumours. However, there are some limitations to its usefulness in certain experimental circumstances and it may not be applicable for studying the more heterogeneous NSGCT.
We have developed a versatile orthotopic xenograft model where NSGCTs develop from cell lines rather than from grafted tumour tissue. The use of cell lines provides a number of distinct advantages. Whereas a clinical specimen from a human patient can only be used to establish a model once, cell lines allow repeated experiments using a reproducible model. The ability to culture and store cells for extended periods of time allows greater flexibility in experimental planning and experiments are not dependent on the availability of suitable patient tissue. Further, the use of cell lines obviates the necessity to maintain tumours by repeated subcutaneous implantation from mouse to mouse. An added benefit is that implantation of tumour cells by injection of single cell suspension is an easy technique to perform, increasing the reproducibility of the model and its application. More importantly, cell lines can be manipulated in vitro, allowing a wide range of investigations to be carried out, including research into the biology of particular genes. Some have argued that injections of cell suspensions do not result in as extensive metastasis as implantation of whole tumour fragments Hoffman, 1999) . Our experience with both the NSGCT model described here and a similar model of human renal cell carcinoma (RCC) also established in our laboratory (Hii et al, 1998) does not agree. In both cases, the rate of development and the pattern and extent of metastasis has been comparable if not superior to fragment implantation models of similar tumours. To compare, the seminoma model described by Konaka et al demonstrated obvious primary tumours and lymph node metastasis 11 weeks after implantation of tumour fragments, but pulmonary and visceral metastasis was not histologically evident. Our NSGCT model, using cell suspensions, repeatedly exhibits large primary tumours and lymph node metastases and histologically visible metastases in the lungs and various other organs. Similarly, our RCC model using cell suspensions yields large primary tumours and macroscopically visible pulmonary metastases within 35 days, whereas the tumour fragment model described by An et al, was reported to require 40 days. We therefore maintain that use of single cell suspensions offers many advantages and does not necessarily reduce the efficacy or relevance of an orthotopic xenograft model. In summary, we have established an orthotopic xenograft model of human NSGCT that is easily performed, reproducible and able to generate rapid results that are clinically relevant. The primary tumours bear many characteristics typical of NSGCT as seen in human patients and are histopathologically recognizable as typical NSGCTs. To the authors' knowledge, this model is the first of its kind to be described and will be invaluable for future studies of factors that influence the development of human NSGCT as well as the development of new therapeutic strategies.
